公开(公告)号：US20230348435A1

公开(公告)日：2023-11-02

申请号：US17999505

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Shogo HASHIZUME

IPC: C07D403/06 ,  A61K45/06 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D403/06 ,  A61K45/06 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).